Whereas inactivating mutations and deletions in ribosomal protein L5 (RPL5, protein also known as uL18) and L22 (RPL22, eL22) are common in multiple tumor types2–9, lesions affecting RPL10 (uL16) have mainly been described in pediatric T-cell acute lymphoblastic leukemia (T-ALL), with additional rare mutations in multiple myeloma4,5. Here, RPL22 is linked to T-cell acute lymphoblastic leukemia.